Related Experiment Video

Updated: Nov 7, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.5K

A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease

Maria Tziastoudi1, Georgios Pissas1, Georgios Raptis2

  • 1Department of Nephrology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.

International Journal of Molecular Sciences
|April 30, 2021
PubMed

Insights

Genetic variants in specific genes like ABCB1 and IL-10 can influence medication effectiveness and side effects in chronic kidney disease (CKD) patients. This pharmacogenetics study highlights genetic predispositions impacting CKD treatment outcomes.

Area of Science:

  • Nephrology
  • Pharmacogenetics
  • Genetics

Background:

  • Chronic kidney disease (CKD) presents a significant global health challenge with high prevalence and morbidity.
  • Current nephrology treatments face issues with medication ineffectiveness and adverse side effects.
  • Understanding genetic influences on treatment response is crucial for personalized medicine in CKD.

Purpose of the Study:

  • To systematically review and meta-analyze pharmacogenetics studies on CKD treatment response.
  • To investigate the association between genetic variants in various genes and patient response to medications.
  • To identify specific genes contributing to treatment effectiveness or adverse events in CKD.

Main Methods:

  • Systematic review and meta-analysis of 29 pharmacogenetics studies.
  • Examination of 11 genes and 16 polymorphisms using dominant, recessive, and additive inheritance models.
  • Subgroup analysis based on patient ethnicity and CKD subtypes (renal transplantation, nephrotic syndrome, lupus nephritis).

Main Results:

  • Strong evidence supports the role of variants in ABCB1, IL-10, ITPA, MIF, and TNF genes.
  • These genetic variants are associated with reduced medication effectiveness or increased adverse events in CKD patients.
  • Identified genetic predispositions influence treatment outcomes in diverse CKD populations.

Conclusions:

  • Genetic variations in ABCB1, IL-10, ITPA, MIF, and TNF play a significant role in CKD pharmacogenetics.
  • These findings suggest a genetic basis for differential responses to CKD medications.
  • Personalized treatment strategies considering genetic profiles may improve CKD patient care.
Keywords:
chronic kidney diseasegenetic associationmeta-analysispharmacogeneticssystematic review

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.1K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.6K

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
113
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
54
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
47
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
59
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
170
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
60